SAN FRANCISCO, CA–(Marketwired – June 23, 2016) – Maxim Analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc., even though its product originated in the deep blue sea. With blockbuster indications like cancer, lupus and Alzheimer’s disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar’s KLH that investors should not ignore.
Included in this interview is: Stellar Biotechnologies Inc. (NASDAQ: SBOT)
The Life Sciences Report: You cover Stellar Biotechnologies Inc. with a target price of $17/share, which represents more than a fourfold increase over the stock’s current valuation, at ~$3.50/share. What’s the value proposition you see here?
Jason McCarthy: Given the current bear market — the correction we’ve seen over the last six months in the biotech markets — we believe the stock is artificially depressed, like most of biotech right now. The stock was closer to $7-8/share not long ago.
Continue reading this interview: Partnerships Propel Stellar Biotechnologies’ Vaccine Technology
About Streetwise Reports — The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Stellar Biotherapeutics Inc. is a billboard advertiser with Streetwise Reports.
Dr. Jason McCarthy: I own, or my family owns, shares of the following companies mentioned in this interview: None. I personally am, or my family is, paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
Please see Streetwise Reports’ terms of use and full legal disclaimer.
Jim Patrick
Publisher
Email contact
